1. Home
  2. KTF vs ACRS Comparison

KTF vs ACRS Comparison

Compare KTF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DWS Municipal Income Trust

KTF

DWS Municipal Income Trust

HOLD

Current Price

$9.17

Market Cap

365.1M

Sector

Finance

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.57

Market Cap

314.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTF
ACRS
Founded
1988
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
365.1M
314.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
KTF
ACRS
Price
$9.17
$3.57
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.75
AVG Volume (30 Days)
103.3K
3.1M
Earning Date
01-01-0001
02-26-2026
Dividend Yield
3.54%
N/A
EPS Growth
N/A
N/A
EPS
0.39
N/A
Revenue
N/A
$15,742,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.40
$1.05
52 Week High
$9.12
$4.89

Technical Indicators

Market Signals
Indicator
KTF
ACRS
Relative Strength Index (RSI) 61.77 N/A
Support Level $9.09 N/A
Resistance Level $9.15 N/A
Average True Range (ATR) 0.05 0.00
MACD 0.01 0.00
Stochastic Oscillator 100.00 0.00

Price Performance

Historical Comparison
KTF
ACRS

About KTF DWS Municipal Income Trust

DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: